Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Roivant Sciences has raised $230.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2023.
Roivant Sciences's investors include Founders Fund, Patient Square Capital, Fidelity, RTW Investments, Palantir Technologies.
Roivant Sciences is headquartered in New York, United States.
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Roivant Sciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Roivant Sciences — Funding & Investors." VCBacked, February 2, 2023, https://www.vcbacked.co/company/roivant-sciences. Accessed August 14, 2026.
VCBacked. (2023). Roivant Sciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/roivant-sciences
{{cite web |title=Roivant Sciences — Funding & Investors |url=https://www.vcbacked.co/company/roivant-sciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated